Literature DB >> 16644615

Application of physiology-based pharmacokinetic and pharmacodynamic modeling to individualized target-controlled propofol infusions.

Andrea N Edginton1, Walter Schmitt, Stefan Willmann.   

Abstract

This study compared the ability of the physiology-based pharmacokinetic (PBPK) model with that of compartmental models used in propofol infusion devices to predict the pharmacokinetics and pharmacodynamics of propofol in various patient groups (children, pregnant women, young men, normal weight adults, and obese adults). With a PBPK model, loss of consciousness (LOC) and recovery of consciousness (ROC) corresponded to a narrow range of brain tissue concentrations (2.2-4.0 mg/L). With the compartmental models, predicted effect concentrations were also within a narrow range at LOC, but were outside the range at ROC. In individuals of normal weight, coefficients of variation (CV) of the predicted brain or effect concentrations at LOC were in a similar range-between 18% and 32%. In obese individuals, however, interindividual CV values for brain or effect concentrations were 41% (PBPK) and 93% (compartmental). This comparison suggests the increased flexibility of PBPK models over compartmental models, the latter of which rely heavily on the patient group from which the model was derived. The incorporation of PBPK models may provide target-controlled infusions with enhanced ability to predict response in a wide variety of patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644615     DOI: 10.1007/BF02850355

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  6 in total

1.  Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling.

Authors:  Olaf Weber; Stefan Willmann; Hilmar Bischoff; Volkhart Li; Alexandros Vakalopoulos; Klemens Lustig; Frank-Thorsten Hafner; Roland Heinig; Carsten Schmeck; Klaus Buehner
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

2.  Propofol Breath Monitoring as a Potential Tool to Improve the Prediction of Intraoperative Plasma Concentrations.

Authors:  Pieter Colin; Douglas J Eleveld; Johannes P van den Berg; Hugo E M Vereecke; Michel M R F Struys; Gustav Schelling; Christian C Apfel; Cyrill Hornuss
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

3.  IMPROVED TRANSFORMATION OF MORPHOMETRIC MEASUREMENTS FOR A PRIORI PARAMETER ESTIMATION IN A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL OF ETHANOL.

Authors:  Martin H Plawecki; Ray Decarlo; Vijay A Ramchandani; Sean O'Connor
Journal:  Biomed Signal Process Control       Date:  2007-04       Impact factor: 3.880

4.  The use of PBPK modeling across the pediatric age range using propofol as a case.

Authors:  Robin Michelet; Jan Van Bocxlaer; Karel Allegaert; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-10-08       Impact factor: 2.745

5.  A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks.

Authors:  Thomas Eissing; Lars Kuepfer; Corina Becker; Michael Block; Katrin Coboeken; Thomas Gaub; Linus Goerlitz; Juergen Jaeger; Roland Loosen; Bernd Ludewig; Michaela Meyer; Christoph Niederalt; Michael Sevestre; Hans-Ulrich Siegmund; Juri Solodenko; Kirstin Thelen; Ulrich Telle; Wolfgang Weiss; Thomas Wendl; Stefan Willmann; Joerg Lippert
Journal:  Front Physiol       Date:  2011-02-24       Impact factor: 4.566

6.  A detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine Renin-Angiotensin-aldosterone system.

Authors:  Karina Claassen; Stefan Willmann; Thomas Eissing; Tobias Preusser; Michael Block
Journal:  Front Physiol       Date:  2013-02-08       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.